Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism

Area of Science:

• Oncology
• Metabolic pathways
• Pharmacology

Background:

• Cancer cells exhibit altered metabolism, presenting a potential drug target.
• Metformin, an established antidiabetes medication, is being investigated for its anticancer metabolic effects.
• Understanding patient-specific metabolic profiles is crucial for targeted cancer therapies.

Purpose of the Study:

• To review the role of metabolite measurement, functional imaging, and gene sequencing in cancer treatment.
• To explore how metabolically targeted drugs, like metformin, affect cancer metabolism.
• To determine methods for selecting patients likely to benefit from metabolic therapies.

Main Methods:

• Review of existing studies on metformin's role in cancer metabolism.
• Analysis of gene expression, metabolomics, and immunohistochemical markers.
• Correlation of metabolic serum markers with treatment response.
• Evaluation of functional imaging and gene sequencing techniques.

Main Results:

• Metformin's potential to modify cancer cell metabolism is under investigation.
• Biomarker analysis (gene expression, metabolomics, immunohistochemistry, serum markers) is used to predict response.
• Window of opportunity studies in breast cancer patients provide insights.
• Metabolite measurement, imaging, and gene sequencing are key tools.

Conclusions:

• Targeting cancer cell metabolism with drugs like metformin is a promising strategy.
• Biomarker analysis is essential for patient selection in metabolic cancer therapy.
• Further research is needed to fully elucidate the role of metabolic targeting in oncology.